Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Director | April 23, 2021 | April 27, 2021 |
| AbbVie Inc.ABBV · Entity 2800 | Director | May 08, 2026 | May 12, 2026 |
| CrowdStrike Holdings, Inc.CRWD · Entity 1172 | Director | September 14, 2026 | September 16, 2026 |
| Freshworks Inc.FRSH · Entity 2193 | Director | October 01, 2026 | October 02, 2026 |
| TARGET CORPTGT · Entity 2967 | Director | June 02, 2020 | June 04, 2020 |
| TELEDYNE TECHNOLOGIES INCTDY · Entity 3158 | Director | June 05, 2020 | June 08, 2020 |
| VERIZON COMMUNICATIONS INCVZ · Entity 116 | Director | April 01, 2026 | April 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date April 23, 2021 · Filed April 27, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 41,542 |
Reported balance
After 2021-04-23 transaction · row 1
1 source rowRow 1 · 2021-04-23 · Grant · Acquired 1,499 · Balance 41,542 F1: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $123.38 · Expires 2031-04-22 | Direct | 7,100 |
Reported balance
After 2021-04-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-04-23 · Grant · Acquired 7,100 · Balance 7,100 F2: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
Filing footnotes · ownership attribution and instrument terms
F1: These are restricted stock units awarded under the Abbott Laboratories 2017 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
F2: Stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
AbbVie Inc.
Report date May 08, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 39,576 |
Reported balance
After 2026-05-08 transaction · row 1
1 source rowRow 1 · 2026-05-08 · Grant · Acquired 1,118 · Balance 39,576 F1: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). |
Filing footnotes · ownership attribution and instrument terms
F1: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).
CrowdStrike Holdings, Inc.
Report date September 14, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stockSEC Table I · non-derivative | Direct | 127,040 |
Reported balance
After 2026-09-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-14 · Exercise / conversion · Acquired 50,000 · Balance 127,040 F1: On July 2, 2026, the Issuer executed a four-for-one stock split with a record date of June 25, 2026, effected in the form of a one-time special stock dividend on each share of the company's Class A common stock. F2: Includes shares to be issued in connection with the vesting of one or more RSUs. |
| Class A common stockSEC Table I · non-derivative | Direct | 97,040 |
Reported balance
After 2026-09-14 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-14 · Sale · Disposed 30,000 · Balance 97,040 F3: This transaction was executed in multiple trades at prices ranging from $237.01 to $237.68. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Includes shares to be issued in connection with the vesting of one or more RSUs. |
| Class A common stockSEC Table I · non-derivative | Direct | 77,040 |
Reported balance
After 2026-09-14 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-09-14 · Sale · Disposed 20,000 · Balance 77,040 F4: This transaction was executed in multiple trades at prices ranging from $238.10 to $238.37. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: Includes shares to be issued in connection with the vesting of one or more RSUs. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.13 · Expires 2028-10-09 | Direct | 150,000 |
Reported balance
After 2026-09-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-09-14 · Exercise / conversion · Disposed 50,000 · Balance 150,000 F5: These stock options were granted on October 9, 2018, and vested in 40 equal monthly installments beginning on October 26, 2018. F1: On July 2, 2026, the Issuer executed a four-for-one stock split with a record date of June 25, 2026, effected in the form of a one-time special stock dividend on each share of the company's Class A common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 2, 2026, the Issuer executed a four-for-one stock split with a record date of June 25, 2026, effected in the form of a one-time special stock dividend on each share of the company's Class A common stock.
F2: Includes shares to be issued in connection with the vesting of one or more RSUs.
F3: This transaction was executed in multiple trades at prices ranging from $237.01 to $237.68. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $238.10 to $238.37. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: These stock options were granted on October 9, 2018, and vested in 40 equal monthly installments beginning on October 26, 2018.
Freshworks Inc.
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 213,662 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 1,513 · Balance 213,662 F1: Represents the grant of fully-vested restricted stock that the Reporting Person elected to receive in lieu of cash compensation under the Issuer's Non-Employee Director Compensation Policy. Grant reflects director compensation for the third quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our common stock over the 30 consecutive trading days immediately preceding October 1, 2026, rounded down to the nearest whole share. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of fully-vested restricted stock that the Reporting Person elected to receive in lieu of cash compensation under the Issuer's Non-Employee Director Compensation Policy. Grant reflects director compensation for the third quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our common stock over the 30 consecutive trading days immediately preceding October 1, 2026, rounded down to the nearest whole share.
TARGET CORP
Report date June 02, 2020 · Filed June 04, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,838 |
Ending reported balance
After 2020-06-04 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2020-06-02 · Exercise / conversion · Acquired 7,415 · Balance 52,253 Row 2 · 2020-06-02 · Sale · Disposed 7,415 · Balance 44,838 Row 3 · 2020-06-04 · Sale · Disposed 10,000 · Balance 34,838 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $60.48 · Expires 2023-01-09 | Direct | 0 |
Reported balance
After 2020-06-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-06-02 · Exercise / conversion · Disposed 7,415 · Balance 0 F1: Option granted under the Target Corporation 2011 Long-Term Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Option granted under the Target Corporation 2011 Long-Term Incentive Plan.
TELEDYNE TECHNOLOGIES INC
Report date June 05, 2020 · Filed June 08, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,305 |
Reported balance
After 2020-06-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-06-05 · Sale · Disposed 1,266 · Balance 7,305 F1: Reporting Person holds 3,305 shares directly and 4,000 shares are held by The Thomas and Roxanne Austin Trust. Shares held directly include 3,182 Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: Reporting Person holds 3,305 shares directly and 4,000 shares are held by The Thomas and Roxanne Austin Trust. Shares held directly include 3,182 Restricted Stock Units.
VERIZON COMMUNICATIONS INC
Report date April 01, 2026 · Filed April 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom StockSEC Table II · derivative / convertible security | IndirectBy Deferred Compensation Plan | 36,492 |
Reported balance
After 2026-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-01 · Grant · Acquired 5,062 · Balance 36,492 F1: Each share of phantom stock is the economic equivalent of one share of common stock and is settled in cash. The shares of phantom stock become payable following the reporting person's termination of service as a director. F2: Includes phantom stock acquired through dividend reinvestment. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of phantom stock is the economic equivalent of one share of common stock and is settled in cash. The shares of phantom stock become payable following the reporting person's termination of service as a director.
F2: Includes phantom stock acquired through dividend reinvestment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 26, 2017 Filed Apr 28, 2017 19:35 UTC | TELEDYNE TECHNOLOGIES INC TDY · Entity 3158 | GrantCommon Stock | 819 | $0.00 | $0.00 |
DisclosureSEC source: 0001094285-17-000052 · wf-form4_149340811580244.xml · nonDerivative · entry 1 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,458 F1 · security: Represents Restricted Stock Units issued to the Reporting Person under the Administrative Rules of the Amended and Restated Teledyne Technologies Incorporated 2014 Incentive Award Plan Related to Non-Employee Director Restricted Stock Unit Awards and Fees. Each Restricted Stock Unit represents a contingent right to receive one share of Teledyne Common Stock. Units vest one year from the date of grant. Shares of common stock will be delivered to the Reporting Person following the vesting date, unless the Reporting Person has made an election to defer delivery of shares until separation from Board service. F2 · price: In determining the number of units the price of $134.26 was used. F3 · balance_after: Reporting Person holds 5,458 shares directly and 2,000 shares are held by The Thomas and Roxanne Austin Trust. Shares held directly include 2,966 Restricted Stock Units as of April 26, 2017. F3 · ownership.direct: Reporting Person holds 5,458 shares directly and 2,000 shares are held by The Thomas and Roxanne Austin Trust. Shares held directly include 2,966 Restricted Stock Units as of April 26, 2017. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 18:30 UTC | TARGET CORP TGT · Entity 2967 | GrantCommon Stock | 2,377 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-17-001069 · doc4.xml · nonDerivative · entry 1 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,080 F1 · kind: Award of restricted stock units pursuant to the Amended and Restated Target Corporation 2011 Long-Term Incentive Plan. F2 · balance_after: Includes dividend equivalents paid on restricted stock units since the date of the reporting person's last filing through the date of the reported transaction that have been reinvested in additional restricted stock units. Read SEC document |
| December 02, 2016 Filed Dec 6, 2016 20:08 UTC | TARGET CORP TGT · Entity 2967 | Exercise / conversionStock Option · Derivative | 3,957 | $0.00 Strike: $58.13 | $0.00 |
DisclosureSEC source: 0001225208-16-042777 · doc4.xml · derivative · entry 3 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,957 shares Expires 2017-01-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Option granted under the Target Corporation Long-Term Incentive Plan. Read SEC document |
| December 02, 2016 Filed Dec 6, 2016 20:08 UTC | TARGET CORP TGT · Entity 2967 | SaleCommon Stock | 3,957 | $77.87 | $308,146.63 |
DisclosureSEC source: 0001225208-16-042777 · doc4.xml · nonDerivative · entry 2 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,522 Read SEC document |
| December 02, 2016 Filed Dec 6, 2016 20:08 UTC | TARGET CORP TGT · Entity 2967 | Exercise / conversionCommon Stock | 3,957 | $58.13 | $230,020.41 |
DisclosureSEC source: 0001225208-16-042777 · doc4.xml · nonDerivative · entry 1 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,479 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes dividend equivalents paid on restricted stock units since the date of the reporting person's last filing through the date of the reported transaction that have been reinvested in additional restricted stock units. Read SEC document |
| May 06, 2016 Filed May 10, 2016 21:18 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 2,974 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-024264 · edgar.xml · nonDerivative · entry 1 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,526 F1 · kind: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 29, 2016 Filed May 3, 2016 21:22 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 3,799 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-023670 · edgar.xml · nonDerivative · entry 1 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,290 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| May 08, 2015 Filed May 12, 2015 21:50 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 2,187 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-007666 · edgar.xml · nonDerivative · entry 1 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,552 F1 · kind: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 24, 2015 Filed Apr 28, 2015 21:09 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 2,793 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-006738 · edgar.xml · nonDerivative · entry 1 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,491 F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| May 09, 2014 Filed May 13, 2014 21:20 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 2,764 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-008314 · edgar.xml · nonDerivative · entry 1 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,365 F1 · kind: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 25, 2014 Filed Apr 29, 2014 21:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 3,535 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-007329 · edgar.xml · nonDerivative · entry 1 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,698 F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| May 06, 2013 Filed May 8, 2013 21:09 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 2,535 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-008008 · edgar.xml · nonDerivative · entry 1 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,601 F1 · kind: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the AbbVie 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 26, 2013 Filed Apr 30, 2013 21:19 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 3,097 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-007418 · edgar.xml · nonDerivative · entry 1 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,163 F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 27, 2012 Filed May 1, 2012 21:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,819 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-007454 · edgar.xml · nonDerivative · entry 1 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,066 F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 29, 2011 Filed May 3, 2011 21:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 2,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-11-007240 · edgar.xml · nonDerivative · entry 1 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,247 F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 26, 2011 Filed Apr 29, 2011 01:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 6,668 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001104659-11-023805 · a4.xml · derivative · entry 4 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 6,668 shares Expires 2011-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 26, 2011 Filed Apr 29, 2011 01:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,500 | $51.36 | $128,402.50 |
DisclosureSEC source: 0001104659-11-023805 · a4.xml · nonDerivative · entry 3 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,080 Read SEC document |
| April 26, 2011 Filed Apr 29, 2011 01:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,168 | $51.37 | $214,093.49 |
DisclosureSEC source: 0001104659-11-023805 · a4.xml · nonDerivative · entry 2 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,580 Read SEC document |
| April 26, 2011 Filed Apr 29, 2011 01:31 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 6,668 | $42.73 | $284,942.31 |
DisclosureSEC source: 0001104659-11-023805 · a4.xml · nonDerivative · entry 1 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 23, 2010 Filed Apr 27, 2010 22:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 2,108 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-10-007454 · edgar.xml · nonDerivative · entry 1 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,080 F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 24, 2009 Filed Apr 28, 2009 22:19 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 2,465 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-09-026801 · a4.xml · nonDerivative · entry 1 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,972 F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the Abbott Laboratories 2009 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 25, 2008 Filed Apr 30, 2008 00:18 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,917 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-08-028086 · a4.xml · nonDerivative · entry 1 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,507 F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 1996 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date on which the director terminates or retires from the Board, dies, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the Abbott Laboratories 1996 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date on which the director terminates or retires from the Board, dies, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 27, 2007 Filed May 1, 2007 22:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,730 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-07-034470 · a4.xml · nonDerivative · entry 1 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,590 F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 1996 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date on which the director terminates or retires from the Board, dies, or the occurrence of a change in control (as defined in the Program). F1 · price: These are restricted stock units awarded under the Abbott Laboratories 1996 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date on which the director terminates or retires from the Board, dies, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 28, 2006 Filed May 2, 2006 21:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 2,127 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-06-030321 · a4.xml · nonDerivative · entry 1 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,860 F1 · kind: These are restricted stock units awarded under the Abbott Laboratories 1996 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date on which the director terminates or retires from the Board, dies, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 22, 2005 Filed Apr 26, 2005 21:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon Shares without par value | 1,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-05-018221 · a4.xml · nonDerivative · entry 1 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,733 F1 · shares: These are restricted stock units awarded under the Abbott Laboratories 1996 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date on which the director terminates or retires from the Board, dies, or the occurrence of a change in control (as defined in the Program). Read SEC document |
| April 23, 2004 Filed Apr 27, 2004 19:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 1,577 | $41.20 | $64,972.40 |
DisclosureSEC source: 0001104659-04-011388 · a4.xml · nonDerivative · entry 1 AUSTIN ROXANNE S · CIK 0001061632 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,844 F1 · kind: These shares represent a restricted stock award under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.